Press Releases

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Filter Releases
 
Feb 7, 2017
- Epidiolex® NDA submission and launch preparation on track -- New Positive Phase 2 glioma data further demonstrates value of cannabinoid pipeline - - Conference call today at 8:30 a.m. EST -...
Jan 30, 2017
LONDON, Jan. 30, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 February, 2017 its first quarter financial results fo...
Dec 5, 2016
- Posters Presented at American Epilepsy Society Annual Meeting -- New data includes key secondary efficacy endpoints - LONDON, Dec. 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its propriet...
Dec 5, 2016
- Three Positive Phase 3 Epidiolex clinical trials reported in 2016 -- NDA submission and launch preparation on track -- Conference call today at 8:00 a.m. EST - LONDON, Dec. 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) ...
Dec 1, 2016
-  Presentations include clinical results from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet Syndrome, as well as additional independent reports from Epidiolex Expanded Access Program sites  - -  GW will also unveil its new U.S. operating name, Greenwich Biosciences, Inc.  ...
Nov 30, 2016
LONDON, Nov. 30, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 December, 2016 its fourth quarter and yea...
Nov 22, 2016
LONDON, Nov. 22, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Of...
Sep 26, 2016
- Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo -  - Today's data represents the third positive Phase 3 pivotal trial for Epidiolex reported in 2016 - ...
Sep 7, 2016
LONDON, Sept. 07, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Off...
Aug 9, 2016
- Positive Phase 3 Epidiolex pivotal trial in Lennox-Gastaut Syndrome (LGS) - - Positive FDA pre-NDA meeting - NDA for Dravet syndrome and LGS on track for H1 2017 submission -             -Conference call today at 8...
Aug 2, 2016
LONDON, Aug. 02, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 9 August, 2016 its third quarter financial results for the ...
Jul 18, 2016
LONDON, July 18, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced offe...
Jul 12, 2016
LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Comp...
Jul 12, 2016
LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject t...
Jun 27, 2016
- Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures compared to placebo - - Today's LGS data follows successful Phase 3 trial in Dravet syndrome announced in March 2016 - ...
= add release to Briefcase

Ways to keep up to date with GW